The United States Food and Drug Administration (FDA) has granted accelerated approval to Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, for Balversa intended for the treatment of metastatic bladder cancer, it was reported yesterday.
The product is now indicated in the United States for the treatment of adult patients having locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration called FGFR3 or FGFR2, and whose condition had progressed during or after being previously treated with platinum-containing chemotherapy. Accelerated approval was based on a phase 2 trial that featured 87 patients having locally advanced or metastatic bladder cancer, with FGFR3 or FGFR2 genetic alterations that had advanced after treatment with chemotherapy.
According to the company, continued approval for its drug for the indication is likely to be based on verification and description of clinical benefit in confirmatory trials. The US FDA stated that patients should be selected for treatment with the Janssen drug using a companion diagnostic device that it has approved.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval